The Non-Canonical IκB Kinases IKKε and TBK1 as Potential Targets for the Development of Novel Therapeutic Drugs

被引：4

作者：

Niederberger, E. ^{[1
]}

Moeser, C. V. ^{[1
]}

Kynast, K. L. ^{[1
]}

Geisslinger, G. ^{[1
]}

机构：

[1] Univ Frankfurt Klinikum, Pharmazentrum Frankfurt ZAFES, D-60590 Frankfurt, Germany

来源：

CURRENT MOLECULAR MEDICINE | 2013年 / 13卷 / 07期

关键词：

Cancer; IKK epsilon; inflammation; interferon regulatory factor; NF-kappa B; TBK1; INTERFERON REGULATORY FACTOR-3; COLLAGEN-INDUCED ARTHRITIS; TANK-BINDING KINASE-1; TOLL-LIKE RECEPTORS; RHEUMATOID-ARTHRITIS; LIVER DEGENERATION; TRANSCRIPTION FACTORS; INSULIN-RECEPTOR; SYNOVIAL TISSUE; MICE LACKING;

D O I：

暂无

中图分类号：

R-3 [医学研究方法]; R3 [基础医学];

学科分类号：

1001 ;

摘要：

I kappa B kinase epsilon (IKK epsilon) and TANK-binding kinase 1 (TBK1) are two non-canonical IKKs which are involved in interferon regulatory factor (IRF) as well as nuclear factor kappaB (NF-kappa B) signaling cascades. Both kinases have already been linked to the pathophysiology of several diseases and therefore been suggested as potential promising targets for the development of therapeutic drugs. In this review, we summarize the roles of IKK epsilon and TBK1 in different diseases and outline therapeutic options for modulation of these kinases.

引用

页码：1089 / 1097

页数：9

共 47 条

[21] Combinatorial Tethering: A Novel Mode to Recruit Non-canonical PRC1 for Normal and Malignant GC B Cell Development
Zeisig, Bernd B.
So, Chi Wai Eric
CANCER CELL, 2016, 30 (02) : 185 - 187
[22] Mechanism of Endogenous Regulation of the Type I Interferon Response by Suppressor of IκB Kinase ε (SIKE), a Novel Substrate of TANK-binding Kinase 1 (TBK1)
Marion, James D.
Roberts, Charlotte F.
Call, R. Jason
Forbes, Jonathan L.
Nelson, Kristina T.
Bell, J. Ellis
Bell, Jessica K.
JOURNAL OF BIOLOGICAL CHEMISTRY, 2013, 288 (25) : 18612 - 18623
[23] NOVEL THERAPEUTIC TARGETS AND POTENTIAL DRUGS FOR BCG INCURABLE NON-MUSCLE-INVASIVE BLADDER CANCER
Zhou Peng
Hu Henglong
Wang Shaogang
JOURNAL OF UROLOGY, 2022, 207 (05): : E934 - E934
[24] Novel therapeutic targets and potential drugs for BCG incurable non-muscle-invasive bladder cancer
Zhou, P.
Hu, H.
Hu, J.
Wang, S.
EUROPEAN UROLOGY, 2022, 81 : S110 - S110
[25] Non-canonical MHC-I peptide binding enables a novel mechanism of HIV-1 escape
Pymm, P.
Illing, P.
Ramarathinam, S.
Hughes, V
McLaren, J.
Sullivan, L.
Price, D.
Brooks, A.
Purcell, A.
Rossjohn, J.
Vivian, J.
EUROPEAN JOURNAL OF IMMUNOLOGY, 2016, 46 : 891 - 892
[26] Design and Synthesis of Novel Aminoindazole-pyrrolo[2,3-b]pyridine Inhibitors of IKKα That Selectively Perturb Cellular Non-Canonical NF-κB Signalling
Riley, Christopher
Ammar, Usama
Alsfouk, Aisha
Anthony, Nahoum G.
Baiget, Jessica
Berretta, Giacomo
Breen, David
Huggan, Judith
Lawson, Christopher
McIntosh, Kathryn
Plevin, Robin
Suckling, Colin J.
Young, Louise C.
Paul, Andrew
Mackay, Simon P.
MOLECULES, 2024, 29 (15):
[27] Non-canonical GLI1/2 activation by PI3K/AKT signaling in renal cell carcinoma: A novel potential therapeutic target
Zhou, Jiancheng
Zhu, Guodong
Huang, Jun
Li, Lei
Du, Yuefeng
Gao, Yang
Wu, Dapeng
Wang, Xinyang
Hsieh, Jer-Tsong
He, Dalin
Wu, Kaijie
CANCER LETTERS, 2016, 370 (02) : 313 - 323
[28] CBX7 A REGULATOR OF SELF-RENEWAL OF HUMAN HSCS AND NOVEL NON-CANONICAL INTERACTIONS AND POTENTIAL THERAPEUTIC OPPORTUNITIES IN AML
Buisman, Sonja
Jung, Johannes
Weersing, Ellen
Dethmers-Ausema, Albertina
Schepers, Hein
Skokowa, Julia
Poot, Raymond
Bystrykh, Leonid
de Haan, Gerald
EXPERIMENTAL HEMATOLOGY, 2018, 64 : S56 - S56
[29] Development of novel Cu(I) compounds with vitamin B1 derivative and their potential application as anticancer drugs
Brandao, Paula
Guieu, Samuel
Correia-Branco, Ana
Silva, Claudia
Martel, Fatima
INORGANICA CHIMICA ACTA, 2019, 487 : 287 - 294
[30] DprE1 and Ddn as promising therapeutic targets in the development of novel anti-tuberculosis nitroaromatic drugs
Paoli-Lombardo, Romain
Primas, Nicolas
Vanelle, Patrice
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY, 2024, 274

← 1 2 3 4 5 →